ShenZhen GTJA Investment Group is the famous VC, which was founded in 2001. The fund was located in Asia if to be more exact in China. The leading representative office of defined VC is situated in the Shenzhen.
The fund has exact preference in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Pharmaceutical, Therapeutics. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most popular portfolio startups of the fund, we may highlight Shanghai Henlius, Mabworks, Akeso Biopharma.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the ShenZhen GTJA Investment Group, startups are often financed by V Star Capital, Northern Light Venture Capital, Initial Capital. The meaningful sponsors for the fund in investment in the same round are V Star Capital, Shenzhen Capital Group, SBCVC. In the next rounds fund is usually obtained by Shenzhen Capital Group, Loyal Valley Capital, GSR Ventures.
Considering the real fund results, this VC is 53 percentage points more often commits exit comparing to other organizations. The fund is constantly included in less than 2 investment rounds annually. The important activity for fund was in 2018. The usual things for fund are deals in the range of 50 - 100 millions dollars. The average startup value when the investment from ShenZhen GTJA Investment Group is 500 millions - 1 billion dollars.
The current fund was established by Dajian Cai. Besides them, we counted 1 critical employee of this fund in our database.
Related Funds
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Kanova | $15M | 25 Jul 2023 | Gusu District, Jiangsu, China | ||
Atom Bioscience & Pharmaceutical | $45M | 05 Jan 2022 | Zhenjiang, Guangdong Province, China | ||
Cloudbreak Therapeutics | $130M | 01 Jan 2022 | Irvine, California, United States | ||
DK MedTech | 31 Dec 2021 | Gusu District, Jiangsu, China | |||
Boan Biotech | $13M | 26 Aug 2021 | Yantai, Liaoning, China | ||
Teligene | $92M | 24 Feb 2021 | Xuanwu District, Jiangsu, China | ||
$10M | 23 Feb 2021 | Shanghai, China | |||
Harbour Biomed | $102M | 09 Jul 2020 | Shanghai, China | ||
$22M | 22 Jan 2020 | Futian District, Guangdong Province |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Kanova | $15M | 25 Jul 2023 | Gusu District, Jiangsu, China | ||
Atom Bioscience & Pharmaceutical | $45M | 05 Jan 2022 | Zhenjiang, Guangdong Province, China | ||
Cloudbreak Therapeutics | $130M | 01 Jan 2022 | Irvine, California, United States | ||
DK MedTech | 31 Dec 2021 | Gusu District, Jiangsu, China | |||
Boan Biotech | $13M | 26 Aug 2021 | Yantai, Liaoning, China | ||
Teligene | $92M | 24 Feb 2021 | Xuanwu District, Jiangsu, China | ||
$10M | 23 Feb 2021 | Shanghai, China | |||
Harbour Biomed | $102M | 09 Jul 2020 | Shanghai, China | ||
$22M | 22 Jan 2020 | Futian District, Guangdong Province |